Compare Medpace Holdings Inc (MEDP) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.82B), while First Trust NASDAQ 100 Technology Index Fund trades at $333 (market cap $4.10B). The key difference: Medpace Holdings Inc is far larger — about 4.1× First Trust NASDAQ 100 Technology Index Fund's market cap, and First Trust NASDAQ 100 Technology Index Fund is more actively traded (264,303 versus 223,093). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and First Trust NASDAQ 100 Technology Index Fund for 40 Days on average.
| MEDP | QTEC | |
|---|---|---|
Market Cap | $16.82B | $4.10B |
Volume | 223,093 | 264,303 |
Sector | Health | Broad Market / Factor |
52-Week High | $630.19 | $340.28 |
52-Week Low | $393.42 | $207.03 |
Typical Hold Time | 14 Days | 40 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $335.82, down 1.31% on the day. Technical indicators show a bullish trend from moving averages but caution from overbought RSI levels. The ETF provides equal-weighted exposure to the technology sector, with recent analysis highlighting its broader sector definition and liquidity advantages.
The outlook for QTEC is supported by bullish technical trends and its role in tech exposure, though overbought conditions and sector volatility present risks. Investment opportunity lies in diversified tech access, but investors face market sensitivity and valuation pressures inherent to technology stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
